Oticon Medical is pleased to share that the company has entered a new chapter with a change in ownership. Impilo, a Nordic investment firm with extensive experience in the med-tech sector, has agreed to acquire Oticon Medical from Demant A/S. As a global leader in bone anchored hearing solutions (BAHS), Oticon Medical welcomes this transition as a strategic opportunity to accelerate innovation, strengthen market position, and continue delivering life-changing hearing care to patients worldwide.
The agreement also secures 10 year long collaboration between Oticon Medical, Impilo, and Demant, including joint development of future sound processors such as the Ponto 6 family and Sentio 2, as well as manufacturing and supply partnerships.
The transition ensures continuity for customers and patients, with no changes to daily operations, local sales, or customer support.
Oticon Medical will move forward as a strategically autonomous business, empowered by Impilo’s commitment to shaping the future of hearing care.
“Impilo shares our values and vision, and as our new owner, brings the investment and strategic focus needed to further strengthen our position in the BAHS market,” says René Govaerts, President & General Manager, Oticon Medical. “We are confident this partnership will help us continue delivering exceptional solutions and support.”
“We are delighted to partner with management on the acquisition of Oticon Medical to accelerate growth, drive innovation, and further improve patient outcomes. The company has established itself as a leading player in the attractive and underpenetrated global BAHS market and has strengthened its position with the recently launched transcutaneous product, Sentio, which has already demonstrated impressive results. We are deeply impressed by the management team’s expertise, their ability to deliver outstanding patient support, and their unwavering commitment to improving patient outcomes. We look forward to our partnership with management and to the journey ahead, advancing the development of cutting-edge BAHS solutions that will further enhance the lives of patients,” says Magnus Edlund, Partner at Impilo.
Oticon Medical remains focused on delivering high-quality products and services that improve hearing and quality of life. With a clear path forward and a committed new owner, the company is well-positioned for future growth.
About Oticon Medical
Oticon Medical is a global company in implantable hearing solutions, dedicated to bringing the power of sound to people at every stage of life. For more than a decade, we have made bone anchored hearing systems more accessible by simplifying the treatment for physicians, audiologists, and patients alike.
We believe that patients and hearing care professionals should be able to choose the best possible solution at any time along the patient journey. We call it “Freedom of Choice” and it has always been paramount to Oticon Medical. This is the reason why our solutions are designed to be compatible whenever possible. As a result, an implant from Oticon Medical stands as a true testament to our unwavering lifelong support.
We work collaboratively with professionals to ensure that every solution we create is designed with our users’ needs in mind. We have a strong passion to provide innovative solutions and support that enhance quality of life and help people live life to the fullest – now and in the future.
Because we know how much sound matters.
About Impilo
Impilo is a Nordic investment company focused solely on investments in lower-mid-market Nordic healthcare companies. It seeks majority buyouts of privately held companies across the pharmaceuticals, MedTech, specialist pharma services and other healthcare & related services industries. Target companies must contribute to the positive and sustainable development of the markets in which they operate, as well as have a credible path to becoming a market leader in their respective niche. Impilo has a well-diversified portfolio of healthcare investments and manages approximately €2 billion of capital from leading international investors.